Enzo Life Sciences Introduces New Portfolio of Clinically Relevant, Validated Antibodies for IHC

Enzo Life Sciences is proud to announce the introduction of three new clinically relevant antibodies for immunohistochemistry detection. When combined with Enzo’s enhanced detection system, our IHC solutions are among the most robust and cost-effective on the market. This furthers Enzo’s capabilities in the rapidly growing segment of Anatomical Pathology, and allows us to enable... Read more

ENZO BIOCHEM REPORTS DELAWARE COURT RULING

NEW YORK, NY, June 29, 2017 – Enzo Biochem Inc. (NYSE: ENZ) reported today that a federal judge for the U.S. District Court for the District of Delaware has entered an order in the actions entitled Enzo Life Sciences, Inc. v. Gen-Probe Incorporated, Enzo Life Sciences, Inc. v. Hologic, Inc., Enzo Life Sciences, Inc. v. Roche Molecular... Read more

Enzo Life Sciences Introduces Innovative Ultra-Sensitive Multiplex IHC Kit

Enzo Life Sciences is pleased to unveil our newest immunohistochemistry product, MULTIVIEW® PLUS (mouse-HRP/rabbit-AP) IHC Kit (Brown/Green). This non-biotin nanopolymer detection system contains reagents and materials that detect and localize antigens in formalin-fixed paraffin-embedded tissues. The new MULTIVIEW PLUS IHC kit optimizes your IHC process by including the entire workflow, from antigen retrieval to visualization.... Read more

Enzo Life Sciences Launches New Compound Library to Provide Essential Standards for Cancer Inhibitor Screening

Enzo Life Sciences is proud to introduce the SCREEN-WELL® Cancer Library, a collection of 275 ready-to-use compounds for use in cancer inhibitor screening and assay development. The SCREEN-WELL® Cancer Library is comprised of compounds that are dissolved at 10 mM in DMSO and aliquoted at 100 µL per well in deep 96-well plates. It contains... Read more